Highly purified add-on cannabidiol (CBD) is approved as Epidiolex® in the USA for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients ≥1 year of age [1] and as Epidyolex® in the UK/EU in conjunction with clobazam for LGS and DS in patients ≥2 years of age [2]. It is additionally approved for TSC in patients ≥2 years of age in the UK/EU without clobazam [2]. The objective of this retrospective chart review study was to evaluate the seizure reduction, retention, and safety profile of CBD treatment without concomitant clobazam in patients with LGS or DS.
7
MAY
MAY
0